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ABBREVIATIONS 
2-DOG 2-deoxy-D-glucose 
AMPA  α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid 
ALS  Amyotrophic lateral sclerosis 
ATP  Adenosine triphosphate 
BSA  Bovine serum albumin 
cAMP  Cyclic adenosine monophosphate 
CNS  Central nervous system 
cRNA  Complementary ribonucleic acid 
EAATs Excitatory amino acid transporters 
EGFR  Epidermal growth factor receptor 
ENaC  Epithelial sodium channel 
FSH  Follicle stimulating hormone 
Gln  Glutamine 
Glu  Glutamate 
GLUT1 Glucose transporter1 
HA  Haemagglutinin 
HECT  Homologous to E6AP-carboxyl-terminus 
HEK293 Human embryonic kidney cells 293 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
IGF-1  Insulin-like growth factor-1 
Nedd4-2 Neuronal cell expressed developmentally downregulated 4-2 
NMDA N-methyl-D-aspartate 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDGF  Platelet derived growth factor 
PDK  3-phosphoinositide-dependent protein kinase 
PI3K  Phosphatidylinositol 3-kinase 
PKB  Protein kinase B 
RISC  RNA induced silencing complex 
RLU  Relative light units 
ROMK1 Renal outer medullary potassium channel 
Ser  Serine 
SGK  Serum and glucocorticoid inducible protein kinase 
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siRNA  Short interference ribonucleic acid 
TGF- β Transforming growth factor-β 
Thr  Threonine 
TM  Transmembrane domain 
VGLUT Vesicular glutamate transporter 
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1 Zusammenfassung 
 
Die Serum- und Glukokortikoid-induzierbare Kinase 1 (SGK1) ist eine 
Proteinkinase welche die Funktion und Expression verschiedener Ionenkanäle und 
Membrantransporter reguliert. Das Gen wird in Tumor- und Fibroblastenzellinien 
unter dem Einfluss von Serum und Glukokortikoiden aufreguliert. Die Kinase wird 
durch Phosphorylierung aktiviert durch Signale die weiter oberhalb in der 
Signalkaskade die PI3 -Kinase aktivieren. Die Phosporylierung erfolgt durch die 
Phosphoinositid-abhängige Kinasen 1 (PDK1) und PDK2. Bei Aktivierung 
phosphoryliert SGK1 ihre Ziele an einer spezifischen Konsensus-Stelle (Arg-Xaa-
Arg-Xaa-Xaa-Ser/Thr) oder indirekt durch die Inhibition der Ubiquitinligase Nedd4-
2. Die Ubiquitinligase Nedd4-2 katalysiert ihrerseits die Anlagerung eins 
Ubiquitinrestes an ihre Ziele, die sie damit für die Degradation durch das 
Proteasom markiert. 
 
Der natriumgekoppelte exzitatorische Aminosäuretransporter EAAT2 ist der 
wichtigste Glutamattransporter im zentralen Nervensystem der höheren 
Vertebraten. EAAT2 hält die extrazelluläre Konzentration des Glutamats unter 
toxischem Niveau. Eine gestörte Expression des Transporters führt zu 
Exzitotoxizität und trägt möglicherweise zu Krankheiten wie etwa der 
amyotrophischen lateralen Sklerose (ALS) bei. SGK1 ist im Gehirn exprimiert, 
interagiert dort mit der Ubiquitinligase Nedd4-2 und moduliert Membrantransporter 
und Ionekanäle. Die vorliegende Studie untersucht ob SGK1 und ihre Isoformen  
SGK2 und 3 sowie die Proteinkinase B (PKB) EAAT2 regulieren. 
 
Dazu wurde die cRNA des EAAT2 allein oder zusammen mit den jeweiligen 
Kinasen im Expressionssystem Xenopus laevis exprimiert und die [3H]-Glutamat 
Aufnahme als ein Maß für die EAAT2-Aktivität gemessen. Funktionelle Studien 
zeigten, dass die EAAT2-Aktivität durch Koexpression sowohl der SGK1 als auch 
ihrer Isoformen 2, 3 und PKB stimuliert wurde. Kürzlich konnte gezeigt werden, 
dass diese Kinasen auch potente Regulatoren des EAAT1 sind. Dieser 
stimulierende Effekt auf die EAAT1-Aktivität wird durch eine direkte 
Phosphorylierung des Transporters an der SGK-Phosphorylierungsstelle und einer 
Interaktion mit der Ubiquitinligase Nedd4-2 verursacht. Da EAAT2 keine SGK1-
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Konsensusstelle enthält wurde untersucht, ob die Regulation des EAAT2 auf einer 
Interaktion mit der Ubiquitinligase Nedd4-2 beruht. In der Tat zeigte sich, dass der 
Transporter durch die Koexpression der Ligase Nedd4-2 inhibiert wird, ein Effekt 
der wiederum durch die Koexpression der SGK1 aufgehoben wird.  Die 
Proteinkinase inhibiert die Ubiquitinligae Nedd4-2 durch ihre Phosphorylierung 
ohne, wie in Western Blots gezeigt, die Abundanz der Ligase zu verändern. Durch 
Chemilumineszenz konnte zudem gezeigt werden, dass die Stimulierung der 
EAAT2-Aktivität durch eine Erhöhung der Expresssion des Proteins an der 
Zelloberfläche verursacht wird. Die Erhöhung der EAAT2 Oberflächenexpression 
durch die Proteinkinase SGK ist möglicherweise ein neuer Mechanismus in der 
Regulation der neuronalen Erregbarkeit. 
 
Der exzitatorische Aminosäuretransporter EAAT4 ist primär in den Purkin´je 
Zellen und im cerebralen Cortex exprimiert. In diesen Zellen bewirkt der 
Transporter niedrige Konzentrationen des Glutamats unter toxischem Niveau. In 
einer vorherigen Studie konnte gezeigt werden, dass EAAT4 Abundanz und 
Funktion durch SGK1 und Nedd4-2 moduliert werden, aber der grundlegende 
Mechanismus konnte dabei nicht aufgeklärt werden. Expressionsstudien in 
Xenopus Oocyten zeigten, dass die [3H]-L-Glutamataufnahme und -
obeflächenexpression durch die SGK1 gesteigert und durch die Ubiquitinligase 
Nedd4-2 vermindert werden. Ziel der vorliegenden Arbeit ist es, den molekularen 
Mechanismus der EAAT4-Modulation durch die Kinase zu erklären. 
 
Im Gegensatz zum EAAT2 besitzt die Sequenz des EAAT4 zwei putative 
SGK1 Konsensus-Stellen am Amino- und Carboxy-Terminus (Thr40 und Thr504) 
die zwischen den verschiedenen Organismen stark konserviert sind. Um die 
potentielle Bedeutung dieser SGK Phosphorylierunsstellen in der EAAT4-
Modulation durch die Proteinkinase aufzuklären wurden beide Stellen deletiert und 
das mutierte Protein allein oder zusammen mit der SGK1 exprimiert. Die Deletion 
beider SGK1 Phosphorylierungsstellen auf dem EAAT4-Protein (T40A, T504A) 
reduzierte den stimulierenden Effekt der Kinase auf die Funktion des Transporters 
und seine Oberflächenexpression. Von den beiden Phosphorylierungsstellen ist nur 
die erste (Thr40) für den stimulierenden Effekt verantwortlich da die T40AEAAT4 
Aktivität und Abundanz nicht weiter durch die Proteinkinase moduliert wird. Die 
SGK1 hat möglicherweise, wie beim EAAT2 beschrieben, durch die Inhibition der 
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Ubiquitinligase Nedd4-2 einen zusätzlichen Effekt auf EAAT4. Die Koexpression 
der SGK1 hebt den inhibierenden Effekt der Nedd4-2 auf und stimuliert dadurch die 
Expression des Transporters. Die Beteiligung der Ubiquitinligase Nedd4-2 an der 
Inhibition des EAAT4 konnte durch RNA-Interferenz nachgewiesen werden. 
 
Die durch RNA-Interferenz vermittelte Inhibition der endogenen Nedd4-2 
(xNedd4-2)- aktiviert die EAAT4-Funktion welche weiterhin durch die zusätzliche 
Expression der SGK1 stimuliert wird. In der Zusammenfassung moduliert die 
SGK1-Kinase die Aktivität des EAAT4 durch die Phosphorylierung des 
Transporters am Thr40 und auf indirektem Wege durch die Inhibition der 
Ubiquitinligase Nedd4-2. Deshalb spielt die SGK1 Proteinkinase möglicherweise 
eine wichtige Rolle bei der Homöostase der neuronalen Erregbarkeit im zentralen 
Nervensystem. 
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2 Summary 
 
The Serum and Glucocorticoid inducible Kinase 1 (SGK1) is a protein kinase 
which regulates the function and expression of several ion channels and 
transporters. It was intially recognized as an immediate early gene whose mRNA 
level is increased in mammary tumour cell and fibroblast cell lines upon serum or 
glucocorticoids. The kinase is activated by phosphorylation in response to signals 
that stimulate phosphatidylinositol 3-kinase. The phosphorylation is mediated by 3-
phosphoinositide-dependent protein kinase1 (PDK1) and PDK2/H-motif kinase. 
Once phosphorylated, the kinase regulates its targets activity through 
phosphorylation at the SGK1 consensus site (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) or 
indirectly through inhibition of the ubiquitin ligase Nedd4-2. Nedd4-2 is an ubiquitin 
protein ligase that mediates binding of ubiquitin to its target proteins which tags 
them for degradation by the proteosome.  
 
The sodium dependent excitatory amino acid transporter EAAT2 is a major 
glutamate carrier in the mammalian central nervous system. EAAT2 maintains the 
level of extracellular glutamate below the excitotoxic level. Defective expression of 
the transporter results in neuroexcitotoxicity that may contribute to neuronal 
disorders such as amyotrophic lateral sclerosis (ALS). SGK1 is expressed in the 
brain and interacts with the ubiquitin ligase Nedd4-2 to modulate membrane 
transporters and ion channels. The present study aimed to investigate whether 
SGK1 and its isoforms SGK2 and SGK3 as well as the related kinase, protein 
kinase B (PKB), regulate EAAT2.  
 
To this end cRNA encoding EAAT2 alone or along with the kinases was 
expressed in Xenopus laevis oocytes and [3H] L-glutamate uptake was determined 
as a measure of EAAT2 activity. Funtional studies demonstrated that EAAT2 
activity is stimulated by coexpression of SGK1, its isoforms SGK2 and SGK3 as 
well as PKB. Regulation of the closely related glutamate transporter EAAT1 was 
recently shown to involve SGK1-3. The effect of these kinases on EAAT1 is 
mediated, in part, by direct phosphorylation of EAAT1 at the SGK1 consensus site 
on the transporter and by interference with the downregulating effect of the ubiquitin 
ligase Nedd4-2. Since EAAT2 does not contain any SGK consensus site, we 
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addressed whether the kinases modulate EAAT2 by impacting Nedd4-2 effects. In 
fact, the function of EAAT2 was diminished by Nedd4-2, an effect abrogated by 
additonal coexpression of SGK1. The kinase inhibits Nedd4-2 through 
phosphorylation without altering Nedd4-2 protein abundance as demonstrated by 
western blotting of whole cell lysates. Chemiluminescence assays revealed that 
stimulation of EAAT2 activity is caused by the enhancement of the transporter 
abundance in the cell surface. Enhanced EAAT2 abundance by SGK1 might 
represent a novel mechanism in the regulation of neuronal excitability. 
 
The exitatory amino acid transporter EAAT4 is predominantly expressed in 
Purkinje cells of cerebellar cortex. In those cells, EAAT4 keeps the level of 
extracellular glutamic acid in synaptic cleft below the toxic level. In a previous study 
EAAT4 abundance and function were shown to be modulated by SGK1 and Nedd4-2 
but the precise mechanism of action remained illdefined. Expression studies in 
Xenopus oocytes demonstrated that EAAT4-mediated [3H] L-glutamate uptake and 
cell surface abundance are enhanced by coexpression of SGK1 and downregulated 
by coexpression of Nedd4-2. The present work aimed to identify the molecular 
mechanism of EAAT4 modulation by the kinase.  
 
In contrast to EAAT2, EAAT4 sequence bears two putative SGK1 consensus 
sites at the amino and the carboxy terminus (Thr40 and Thr504) that are conserved 
among several species. To investigate the role of these putative SGK1 
phosphorylation sites in EAAT4 modulation by SGK1, both sites were deleted and the 
mutated protein expressed alone or together with the kinase. Disruption of both SGK1 
phosphorylation sites on EAAT4 (T40AT504AEAAT4) reduced the kinase effect on 
transporter function and plasma membrane expression. From both phosphorylation 
sites, Thr40 appears to be responsible for the stimulatory effect since T40AEAAT4 
activity and abundance was not further modulated by the kinase. SGK1 may 
additionally modulate transport through inhibition of the ubiquitin ligase Nedd4-2 as 
observed with the EAAT2 transporter. Coexpression of SGK1 inhibits the 
downregulating effect of Nedd4-2 on EAAT4 and thus stimulates the expression of the 
transporter. The significance of Nedd4-2 in the downregulation of EAAT4 was 
demonstrated by silencing intrinsic (Xenopus) Nedd4-2.  
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RNA interference-mediated silencing of endogenous Nedd4-2 (xNedd4-2) 
increased EAAT4 activity that was further stimulated upon additional SGK1 
expression. In conclusion, the SGK1 kinase modulates EAAT4 activity through 
phosphorylation of the transporter at Thr40 and indirectly through inhibition of the 
ubiquitin ligase Nedd4-2. Hence SGK, through the regulation of EAAT2 and EAAT4 
activity and expression might maintain proper neuronal excitability in the central 
nervous system.  
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3 Introduction 
3.1 The Serum and Glucocorticoid inducible Kinase SGK1 
 
The Serum and Glucocorticoid inducible protein Kinase 1 (SGK1) was 
identified in 1993 as an immediate early gene whose mRNA level increases 
noticeably within 30 minutes when mammary tumour or fibroblast cells are 
stimulated with serum or glucocorticoids1-3. SGK1 gene transcription was also 
shown to occur rapidly in response to many agonists like mineralocorticoids4-6, 
follicle stimulating hormone (FSH)7,8, transforming growth factor (TGF- β)9,10, 
thrombin11, hypertonicity12-14, high glucose9,11 and neuronal injury or 
excitotoxicity15,16. 
 
SGK1 is a member of the ‘AGC’ subfamily of serine/threonine protein 
kinases, which include protein kinase A (PKA) or adenosine 3’, 5’ monophophate 
(cAMP)-dependent protein kinase, protein kinase G (PKG) or guanosine 3’, 5’ 
monophosphate (cGMP)-dependent protein kinase and isoforms of protein kinase C 
(PKC). SGK1 is present in the genomes of all eukaryotic organisms examined so 
far, including Caenorhabditis elegans, Drosphila, fish and mammals. Structure of 
SGK1 has been highly conserved through evolution like many other protein 
kinases8,13,17. 
 
There are two other isoforms of SGK1 that have been identified in mammals 
and are named as SGK2 and SGK3. The catalytic domains of SGK2 and SGK3 
isoforms share 80% amino acid sequence identity with one another and with 
SGK114. The human gene encoding SGK1 was found in chromosome 6q2317. The 
gene encoding SGK2 was identified in chromosome 20q12 and SGK-like gene 
which encodes a protein having predicted amino acid sequence identical to that of 
human SGK318 was found in chromosome 8q12.2.  
 
SGK1 is expressed in all human tissues that have been studied including the 
pancreas, liver, heart, lung, skeletal muscle, placenta, kidney and brain13 but SGK1 
is not expressed in all cell types within those tissues. For example, SGK1 transcript 
levels are found high in acinar cells in the pancreas19. High transcript levels of 
SGK1 are also found in the distal tubule and collecting duct of the kidney and in 
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thick ascending limb epithethial cells9. The expression of SGK2 mRNA is restricted 
in human tissues. It express most abundantly in liver, kidney and pancreas20. As 
like SGK1, SGK3 mRNA is present in all human and murine tissues examined but 
expression is particularly high in the mouse heart and spleen and in the embryo20,21.  
 
SGK1 has been observed as cytosolic in differentiated cells such as luteal 
cells22,23 or in tumour cells arrested in the G1 phase of the cell division cycle by 
glucocorticoids24. It has also been observed as nuclear in proliferating glomerulosa 
cells22,23 or mammary tumour cells during the S and G2-M phases of the cell cycle23. 
However, the localization of SGK1 in any given cell is regulated by extracellular 
signals. Thus, in serum-stimulated mammary epithelial cells, the endogenously 
expressed SGK1 is nuclear, but becomes cytosolic after the inhibition of 
phophatidylinositol (PI) 3-kinase. Translocation from the cytosol to the nucleus also 
occurs in response to serum stimulation of HEK293 or COS cells transfected with 
SGK125.  
 
SGK1 is activated by phosphorylation through a signaling cascade including 
phosphatidylinositol (PI) 3-kinase and phosphoinositide dependent kinase PDK1 
and PDK2/H-motif kinase. While PDK1 phosphorylates SGK1 at 256Thr, PDK2/H-
motif kinase phosphorylates the kinase at 422Ser. SGK2 and SGK3 may similarly be 
activated by PDK1 and PDK2/H-motif kinase. The equivalent phosphorylation sites 
for SGK2 and SGK3 are found at 193Thr/356Ser and 253Thr/419Ser, respectively14,20,25. 
 
Replacement of the serine at position 422 by aspartate in the human SGK1 
leads to the constitutively active S422DSGK1 whereas replacement of lysine at 
position 127 with asparagine leads to the constitutively inactive K127NSGK1. 
Analogous mutations in SGK2 and SGK3 lead to the constitutively active S356DSGK2 
and S419DSGK3, and the constitutively inactive K64NSGK2 and K191NSGK314. 
 
SGK isoforms resemble PKB in the substrate specificity, recognizing a serine 
or threonine residue lying in Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr sequence (where Xaa is 
a variable amino acid) and thereby phosphorylating it14,20,25.  
 
SGK1 has a considerable physiological role through the regulation of 
transporters and ion channels. Sodium channel conductance stimulated by SGK1 
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may result in cell volume regulation12,13,26. SGK1 mediated activation of sodium 
channels leads to Na+ entry which in turn depolarizes the cell membrane. The 
depolarized cell membrane allows the entry of chloride ions and the accumulation 
of NaCl that further increases the intracellular osmolarity. The osmotic gradient 
makes water to enter the cell by which the volume of cell increases27,28. SGK1 was 
found to stimulate Na+, K+ and 2Cl- cotransporter activity in the thick ascending limb 
of the kidney, a key nephron segment in urinary concentration, which is of 
importance in renal Na+ reabsorption9. Abundant SGK1 gene transcription has been 
observed in diabetic nephropathy10,11,29, fibrosing pancreatitis13 and inflammatory 
bowel disease19 but SGK1 involvement in the formation of abnormal fibrosis tissues 
remains to be established.  
 
Moreover SGK1 and its isoforms are well proved in stimulating the activity 
and the cell membrane abundance of several transporters and ion channels. For 
instance, SGK isoforms regulate the epithelial Na+ channel, ENaC5, the voltage-
gated Na+ channel, SCN5A30, the K+ channels ROMK131, KCNE1/KCNQ132 and 
Kv1.333-35, the Na+/H+ exchanger NHE336, the dicarboxylate transporter NaDCT37, 
the glutamate transporters EAAT138, EAAT339, EAAT440 and EAAT541 and the 
Na+/K+-ATPase42. The regulatory activity of SGK1 plays a diverse role in essential 
cell functions such as epithelial transport, excitability, cell proliferation and 
apoptosis.  
 
SGK1 might regulate epithelial Na+ transport via enhancing ENaC 
activity5,26,43 which has been proven to regulate transepithelial Na+ transport in 
kidney, lung and colon44. The K+ channel KCNQ4 maintains electrical excitability in 
inner and outer hair cells of the inner ear and its activity is significantly stimulated 
by SGK1. KCNQ4’s function is responsible for hearing ability and loss-of-funtion 
mutations in KCNQ4 gene leads to hearing loss45,46. Hence SGK1 mediated 
stimulation of KCNQ4 activity might be necessary for excitability and it could 
contribute to the beneficial effect of glucocorticoids in hearing loss or vertigo47,48. 
The role of SGK1 in the regulation of excitatory amino acid transporters (EAAT1, 3-
5) is well established38,39,41. The excitatory amino acid transporters maintain 
glutamate below toxic levels in the synaptic cleft of CNS and prevent severe 
neurological diseases such as amyotrophic lateral sclerosis49-52 and ischemia53-55.  
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The influence of SGK1 in regulation of K+ channel further indicates its 
importance in cell proliferation33-35. K+ channels are considered to be important to 
maintain the cell membrane potential which is in turn required for proper function of 
the Ca2+ release-activated Ca2+ channel (ICRAC)56. ICRAC mediates Ca2+ entry upon 
stimulation of cells with a wide variety of mitogenic factors, a prerequisite for 
triggering cell proliferation57. SGK1 has been found involving in antiapoptotic 
pathway in part to phosphorylation of forkhead transcription factors, such as 
FKRHL121,58. SGK1 has also been shown to inhibit apoptosis of breast cancer 
cells59.  
 
To date, two modes of SGK1 action in regulating transporters and ion 
channels have been identified. It either regulates transporters by phosphorylating 
them at the putative consensus site (Arg-Xaa-Arg-Xaa-Xaa-Ser/Thr) or by inhibiting 
the downregulating effect of protein ubiquitin ligase Nedd4-2. These two modes of 
regulation of SGK1 were observed in epithelial Na+ channel, ENaC60,61 (Figure 1). 
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Figure 1 Schematic model showing molecular mechanisms of ENaC regulation by 
SGK1. Aldosterone binding to the mineralocorticoid receptor (MR) can stimulates the 
transcription of SGK1 as well as ENaC. Insulin or Insulin-like growth factor (IGF-1) 
phosphorylates SGK1 at Ser422 through PI3 kinase and PDK2/H-motify kinase 
signaling cascade. Activated (phosphorylated) SGK1 enhances ENaC plasma 
membrane abundance either directly by phosphorylating the channel or indirectly by 
inhibiting the downregulating effect of the ubiquitin ligase Nedd4-2.  
 
3.2 The Protein Kinase B 
 
The serine/threonine kinase Akt or protein kinase B (PKB) was discovered in 
1991 in two independent lines of research. Bellacoasa’s group cloned the cellular 
homologue of the v-akt oncogene from a transforming retrovirus (AKT8) in 
spontaneous thymoma of the AKR mouse and named its product as c-AKT62,63. 
Similarly Akt/PKB cDNA was cloned by Coffer’s group while searching for novel 
members of the protein kinase C (PKC) and by Jones’s groups while studying 
protein kinase A (PKA) superfamily as possible participants in signal transduction 
cascades64,65. Jones’ group isolated a cDNA that encoded a protein kinase, termed 
RAC (related to the A and C kinases)65. The newly found kinase contains 
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consensus sequences characteristic of a protein kinase catalytic domain and shows 
73% and 68% similarity to PKC and PKA respectively65.  
 
Three major isoforms of Akt/PKB namely, Akt1/PKBα, Akt2/PKBβ and 
Akt3/PKBγ encoded by three separate genes have been found in mammalian 
cells66-69. These three isoforms have greater than 85% sequence identity and share 
the same protein structural organization. The first 100 amino acids of amino-
terminal tail bear a pleckstrin homology (PH) domain that binds phospholipids. A 
short glycine-rich region that bridges the PH domain to the catalytic domain follows 
the PH domain. The last 70 amino acids of carboxy terminal tail contain a putative 
regulatory domain. All three Akt/PKB isoforms possess conserved threonine and 
serine residues (T308 and S473 in Akt1/PKBα)66-69.  
 
Akt/PKB isoforms are ubiquitously expressed in mammals, although the levels of 
expression vary among tissues66-71. Akt1/PKBα is the predominant isoform in most 
tissues including brain where it is markedly increased in regenerating neurons. 
Akt2/PKBβ expression is observed high in insulin-responsive-tissues comprising 
skeletal muscle, heart, liver and kidney66. Akt2/PKBβ expression is further 
substantiated in developing embryos70. In contrast to the first two isoforms, 
Akt3/PKBγ shows restricted pattern of expression. It expresses at high levels in 
testis and brain and low levels in the adult pancreas67,69,71.  
 
Akt/PKB isoforms can be rapidly activated by platelet derived growth factor 
(PDGF) studies in rodent fibroblasts showed that Akt/PKB is directly activated by 
PI3 kinase, which is activated by growth factor receptors through binding of its 
regulatory subunit to phosphotyrosine residues in the receptor72,73. This is strongly 
suggested by the dependency of PKB on tyrosines Y740 and Y752 in the PDGF 
receptor that had been identified as the binding sites for the p85 regulatory subunit 
of PI3 kinase73. PI3 kinase mediated PKB activation was also proved by the 
inactivation of PKB by the PI3 kinase inhibitors wortmannin and LY9400272-74. 
Mechanism of Akt1/PKBα activation is recognized well and some studies 
demonstrate that same mechanism is true for both Akt2/PKBβ and Akt3/PKBγ 
according to different tissues and in response to different stimuli70,75,76.  
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Akt/PKB posses two phosphorylation sites, at carboxy-terminal tail (S473) 
and at activation loop of the kinase domain (T308), which are essential for the 
kinase activation by growth factors. Akt/PKB is activated by growth factors through 
the PI3 kinase signaling cascade. The growth factor which is recognized by tyrosine 
kinase receptors activates PI3 kinase which in turn catalyzes production of 
phophoinositides phosphorylated at position 3 (PI(3,4,5)P3). PI(3,4,5)P3 binds to 
the PH domain of PDK1 and Akt/PKB and also activates PDK2/H-motif kinase. 
Activated PDK1 and PDK2/H-motif kinase phosphorylate Akt/PKB at S473 and 
T308 respectively and anchor the kinase to the plasma membrane (Figure 2)75.  
 
Activation of PKB by PI3 kinase
PDK1PI (3,4,5)P3 PKB
GF
PI (3,4,5)P3
PI3 kinase
PDK2
PKBPI (3,4,5)P3
PH PKB
P P
T308 S473
 
 
Figure 2 An outline of PKB activation by growth factor through PI3 kinase signalling 
cascade.  
 
The PI3 kinase mediated Akt/PKB activation suggests that Akt/PKB might be 
involved in growth factor mediated cell survival77-80 and might be capable of 
regulating basic metabolic functions such as protein and lipid synthesis, 
carbohydrate metabolism and transcription75. The Akt/PKB isoform used in this 
study is Akt1/PKBα. Specifically T308D, S473DPKB mutant was employed and mimics 
the activated (phosphorylated) state by PDK1/2.  
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3.3 The Ubiquitin ligase Nedd4-2 
 
The ubiquitination of proteins is an essential step in the degradation or 
processing of intracellular proteins in eukaryotic cells. This selective event takes 
place by conjugation of multiple ubiquitin molecules with target proteins. The 
ubiquitinated protein is in turn a target for a large 26S protease complex known as 
proteosome81,82 (Figure 3). The covalent attachment of ubiquitin, a highly conserved 
76-amino acid polypeptide, to lysine residues of a substrate protein is required for 
proteosomal degradation81,83,84.  
 
Protein ubiquitination involves the cascade of three classes of enzymes: the 
ubiquitin-activating enzyme E1, the ubiquitin-conjugating enzyme (Ubc) or E2 and 
the ubiquitin-protein ligase E381. The E1 enzyme first activates an ubiquitin through 
the formation of a high-energy thiol ester bond between the carboxyl-terminal 
glycine of ubiquitin and the thiol group of a cysteine residue of E1. The ubiquitin is 
then transferred to a cysteine residue on one of the E2 members. The E2 enzymes 
may catalyse the attachment of the single ubiquitin to a substrate protein directly, or 
transfer the ubiquitin to E3 proteins. The E3 enzyme can catalyse the formation of 
an isopeptide bond between the carboxyl-terminal glycine of ubiquitin and the ε-
amino group of lysine residues on a target protein. The attachment of additional 
ubiquitins by E3 enzyme eventually results in a multiply ubiquitinated substrate. The 
E3 is therefore believed to recognize specific substrate proteins that do not 
associate with E2 alone85.  
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Figure 3 Protein ubiquitination involves the cascade of three classes of enzymes E1-
the ubiquitin-activating enzyme, E2- ubiquitin-conjugating enzyme and E3-ubiquitin 
ligase enzyme. 26S proteosome recognizes the ubiquitinated protein and degrades it.  
 
Human associated protein (E6AP) is an E3 enzyme that has been identified 
as functioning as an ubiquitin-protein ligase of tumour suppressor protein P53 in the 
presence of E6 onco-protein from human papilloma virus types 16 and 1886,87. 
Putative E3 proteins contain a conserved region of approximately 350 amino acids 
homologous to the carboxyl-terminus of E6AP, termed ‘the homologous to E6AP 
carboxyl-terminus’ (HECT) domain88. Nedd4 ubiquitin protein ligase is one of the 
HECT-E3 proteins89 and has been well studied in regulating ion channels and 
transporters including ENaC90-93 and EAAT138. Nedd4 [‘NPC (Neuronal Precursor 
Cells)-Expressed, Developmentally Down-regulated 4’] gene was identified in 1992 
as a developmentally regulated mouse gene highly expressed in early embryonic 
central nervous system. Nedd4 expression is not only restricted to the embryonic 
CNS94, but is also expressed abundantly in tissues such as cortical collecting ducts 
in kidney95,96 and lung epithelia which are important tissues for Na+ channel 
function94.  
 
The Nedd4 has two isoforms namely Nedd4-1 (also named Nedd4, 
KIAA0093, or RPF1) and Nedd4-2 (also known as KIAA0439, LDI-1, Nedd4La, 
Nedd18, or Nedd4-L). The isoforms of Nedd4 has been studied intensively in the 
regulation of epithelial Na+ channel (ENaC)96-98. Nedd4-1 has one N-terminal 
calcium-dependent lipid binding domain (C2), a domain homologous to the E6-AP-
COOH-terminal (HECT) and three to four WW domains with approximately 40 
Protein Ubiquitination
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U
U
E1U E2U E3U
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amino acids which are protein-protein interaction modules found in a variety of 
proteins98. WW domains derive their name from the presence of two highly 
conserved tryptophan (W) residues and a conserved proline residue in the 
sequence of ~35 amino acids99. These domains have a preference for binding small 
proline-rich sequences present in the target proteins called PY motifs, the most 
common of which is PPxY99 (P being proline and Y tyrosin residues). WW domains 
of some proteins can bind to alternative proline-rich motifs like PPLP100, L being a 
leucin residue. The catalytic region of Nedd4, the HECT domain, contains a 
conserved cysteine residue that serves as an active site for the formation of thiol 
ester bond with an ubiquitin87,88,101. 
 
Nedd4-2 in the rat and mouse species has three WW domains, whereas in 
humans there are four WW domains which may be due to alternative splicing, as 
there is evidence for multiple transcripts in human Nedd4-1102. Nedd4-2 has four 
WW domains and a HECT domain. Only Xenopus laevis Nedd4-2 comprise a C2 
domain, whereas such a domain appears to be lacking in mouse Nedd4-298. Figure 
4 illustrates the structure of human and Xenopus Nedd4-2. 
 
Nedd4-2 Structure 
WW HECTWWWWWW
Human Nedd4-2
C2 WW HECTWWWWWW
Xenopus Nedd4-2
 
 
Figure 4 Schematic illustration of human and Xenopus Nedd4-2. Both human and 
Xenopus Nedd4-2 contain four WW domains and a HECT catalytic domain. Only 
Xenopus Nedd4-2 bears a C2 domain.  
 
Nedd4-2 has several SGK1 phosphorylation sites which can be 
phosphorylated by SGK1 that leads to inactivation of the ubiquitin ligase (Figure 5). 
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By inactivating Nedd4-2, SGK1 can enhance the expression and activity of 
transporters (EAAT4)40) and ion channels (ENaC)60) indirectly.  
 
xNedd4-2 C2 WW HECTWWWWWW
Ser
338
Ser
444
Human
Xenopus
Nedd4-2
Nedd4-2
Mouse Nedd4-2
377...RLRSCS...382
333...RLRSCS...338
207...RLRSCS...212 323...RPRSLS...328
463...RPRSLS...468
439...RPRSLS...444
Consensus RXRXX(S/T) RXRXX(S/T)
SGK1 consensus sites in Nedd4-2
 
 
Figure 5 The xNedd4-2 sequence posses two putative SGK1 phosphorylation sites at 
Ser338 and Ser444. Consensus sites of SGK1 in mouse and human Nedd4-2 are also 
indicated below. 
 
Nedd4-2 mediated regulation is well studied in ENaC. The WW domains 3 and 
4 of Nedd4-2 bind to the PY motif of ENaC and ubiquitinate the channel. Upon 
ubiquitination, ENaC is internalized and deubiquitinated. The deubiquitnated ENaC is 
either degraded by the lysosomes or relocated to the plasma membrane97. Figure 6 
shows the ENaC downregulation by Nedd4-2.  
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Figure 6 Nedd4-2 recognizes (1), ubiquitinates (2) and thus internalizes (3) the 
epithelial Na+ channel ENaC.  
 
3.4 Glutamatergic Neurotransmission 
 
The amino acid L-gutamate is a major excitatory neurotransmitter in the 
mammalian central nervous system and is involved in most aspects of normal brain 
function including cognition, memory and learning103-105. Glutamate also plays major 
roles in the development of the central nervous system, including synapse induction 
and elimination, and cell migration, differentiation and death106. It has been 
implicated in many important physiological processes such as developmental 
plasticity, pathological conditions including epilepsy, cerebral ischemia, amyotrophic 
lateral sclerosis, Alzheimer’s disease, Parkinson’s disease and schizophrenia107. 
 
The glutamatergic neurotransmission begins with the release of glutamate 
from the synaptic vesicles to the synaptic cleft by exocytosis. The released 
glutamate activates three families of protein receptors107. One family of glutamate 
receptors are NR1, NR2A, NR2B, NR2C and NR2D. They are collectively known as 
NMDA-receptors because they are activated by the glutamate analogue N-methyl-
D-aspartate (NMDA). Second family of receptors is called AMPA and kainate 
receptors, which are activated by α-amino-3-hydroxy-5-methyl-4-isoxazole 
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propionic acid (AMPA) and kainate respectively. AMPA-receptors are divided into 
subgroups namely GluR1-4 and kainate receptor’s subgroups are GluR5-9, KA1 
and KA2. The NMDA and AMPA/kainate receptors are glutamate gated ion 
channels and are termed as ionotropic glutamate receptors. G-protein coupled 
receptors comprise the third family of glutamate receptors and are named as 
metabotropic receptors which are subdivided into groups I (mGluR1 and mGluR5), 
group II (mGluR2 and mGluR3) and group III (mGluR4, mGluR6, mGluR7 and 
mGluR8)107. The glutamate neurotransmission is terminated by uptake of excessive 
glutamate from the synaptic cleft.  
 
Glutamate uptake is accomplished by means of glutamate transporter 
proteins which use the electrochemical gradients across the plasma membrane as 
driving forces for uptake108. Both neurons and glial cells express glutamate 
transporters (EAATs). Glutamate taken up by the cells may be used for metabolic 
purposes (protein synthesis, energy metabolism, ammonia fixation) or be reused as 
transmitter107. Glutamate is transported into synaptic vesicles by a vesicular 
glutamate transporter (VGLUT) and subsequently released by exocytosis109-112. In 
astrocytes, glutamate taken up from the extracellular fluid may be converted to 
glutamine which is released to the extracellular fluid, taken up by neurons and 
reconverted to glutamate inside neurons107 (Figure 7). 
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Figure 7 A schematic outline of glutamatergic neurotransmission. Upon an action 
potential glutamate (Glu) contained in vesicles in the presynaptic neurons is released 
to the synaptic cleft. Released glutamate activates glutamate (metabotropic and 
ionotropic-NMDA) receptors present on the post-synaptic neurons. To terminate 
transmission and in order to avoid excitotoxicity, glutamate is taken up by excitatory 
amino acid transporters (EAATs). Glutamate taken up by the cells may be stored in 
transmitter vesicles or be used for metabolic purposes. In neurons glutamate is 
transported into synaptic vesicles by a vesicular glutamate transporter (VGLUT). In 
astrocytes glutamate may be converted to glutamine (Gln). Released glutamine may 
be taken up by transporters (SN1) on neurons and converted to glucose.  
 
The brain contains huge amounts of glutamate (about 5-15 mmol per kg wet 
weight depending on the region) and only a tiny fraction of this glutamate is 
normally present extracellularly113. Glutamate uptake is a mechanism responsible 
for the maintenance of low extracellular concentrations of glutamate in the synaptic 
cleft. A defect in uptaking glutamate from the synaptic cleft results in the 
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accumulation of glutamate that causes neuroexcitotoxicity and neurodegeneration 
which is seen in epilepsy114-116, ischemia53-55 and amyotrophic lateral sclerosis49-52. 
 
3.4.1 Excitatory Amino Acid Transporters (EAATs) 
 
Excitatory amino acid transporters (EAATs) in the central nervous system 
(CNS) maintain extracellular glutamate concentration below excitotoxic levels and 
contribute to the clearance of glutamate released during neurotransmission106. At 
least five structurally distinct subtypes of human glutamate transporters, EAAT1 – 
EAAT5 have been identified and characterized by molecular cloning.  
 
In 1992, three groups simultaneously isolated cDNA clones of these 
transporters. Kanner’s group purified a transport protein from rat brain with 
biochemical methods117 and isolated a cDNA clone identified as GLT1 by using 
sequence information derived from a peptide fragment of this protein 118. Hediger’s 
group used expression cloning to isolate a clone called EAAC1 (Excitatory Amino 
Acid Carrier) from a cDNA library prepared from rabbit intestine 119.  
 
Stoffel’s group while isolating a uridine diphosphate (UDP) galactose: 
ceramide galactosyltransferase from brain, always observed a co-
chromatographing protein. After analysis of its sequence, they found a high 
homology to a bacterial H+-dependent EAA transporter. A cDNA clone encoding a 
protein called GLAST (glutamate and aspartate transporter) was then isolated120. 
Amara’s group isolated the human homologues of all three transporters and 
introduced the term EAAT1-3 for Excitatory Amino Acid Transporter121. EAAT1 is 
homologue of GLAST, EAAT2 is homologue of GLT1 and EAAT3 is homologue of 
EAAC1. The sequence similarity of these transporters was used to obtain two other 
EAA transporter clones called EAAT4 and EAAT5122,123. 
 
EAATs have been isolated from a variety of eukaryotic species, including 
human (hEAAT1-5)121-124, rat (GLAST-1, GLT-s, rEAAC1)118,120,125, mouse 
(mEAAT1, mEAAT2, mEAAC1, mEAAT4)126-131, rabbit (EAAC1)119, Salamander 
(sEAAT1, -2A, -2B, -5A, -5B)132, cow (bGLAST)133 and Drosophila melanogaster 
(dEAAT)134. In prokaryotes, gene encoding proton-dependent L-glutamate 
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transporters from E.coli (GltP), Bacillus stearothermophilus (GltT)135,136, and 
Bacillus caldotenax (GltT) and dicarboxylic acid transporter (DctA) from Rhizobium 
meliloti137 are shown relatively high homology to the eukaryotic EAA carriers108.  
 
EAATs are predominantly localized on presynaptic neurons and glial cells106. 
EAAT1 and EAAT2 are distributed abundantly on astrocyctic plasma membranes 
throughout the CNS138. Among the five subtypes EAAT2 is the most abundant 
glutamate transporter localized in the CNS. EAAT1 is the second abundantly 
present transporter107. EAAT3 is found in highest concentrations in the 
hippocampus, cerebellum (Purkinje cells) and basal ganglia139,140. EAAT4 is 
selectively expressed on a GABAergic cell type, the cerebellar Purkinje cell and 
appears concentrated adjacent to excitatory synapse where glial cell membranes 
contact dendritic spines141-143. EAAT5 appears to serve a unique signalling function 
in photoreceptors of retina122,132,144. Three other EAATs are also been found in 
retina. They are EAAT1 in the Müller glial cells, EAAT2 in cone photoreceptors and 
cone bipolar cells, and EAAT3 in horizontal cells, amacrine cells and ganglion 
cells145,146.  
 
Hydropathy analysis of excitatory amino acid transporters predicts six 
strongly hydrophobic transmembrane helices in the N-terminal half of the 
transporter and anywhere from 4-6 membrane-spanning regions in the C-terminal 
half108. 
 
The conserved amino acid sequences of EAATs evidences to be highest in 
the C-terminal half of the transporter and in the putative transmembrane domains, 
whereas the least conserved regions are at the N and C termini108. ‘AAXFIAQ’ motif 
in the C-terminal half of the transporter is noticeably conserved in both eukaryotic 
and prokaryotic members of this family and plays important role in transporter 
function108. EAAT1-3 have two consensus sites for N-linked glycosylation (NXS/T) 
located in a large hydrophilic loop between 3rd and 4th transmembrane domains 
(TMs). EAAT4 and EAAT5 have three and one N-linked glycosylation sites 
respectively108.  
 
Among the five glutamate transporters, only EAAT1 and EAAT4 have 
SGK1/PKB consensus sites on their sequence. EAAT1 has a consensus SGK1 
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phosphorylation site at Thr482 and EAAT4 has two putative SGK1 phosphorylation 
sites at Thr40 and Thr504. PKC is found to phosphorylate and internalize EAAT1147-
150
 and EAAT2149,151-153. PKC mediated phosphorylation reduces the activity and 
cell surface expression of both EAAT1147-150 and EAAT2147,149,151-153. A 43 amino 
acid domain in the C terminal of EAAT2 is necessary for PKC-dependent 
internalization149. PKC activation increases EAAT3 mediated activity in C6 glioma 
cells and in Xenopus oocytes154 and cell surface expression in neuron-enriched 
cultures149,155, but controversially, Trotti et al found that activation of PKC 
decreases EAAT3 mediated activity and cell surface expression in Xenopus 
oocytes or in Madin-Darby Canine kidney cells156. The precise mechanism of PKC 
mediated regulation of glutamate transporters is still elusive.  
 
Transportation of glutamate by EAATs is an electrogenic phenomenon. The 
inward movement of glutamate across the membrane is thermodynamically coupled 
with the influx of two or three sodium ions and one proton and the efflux of one 
potassium ion157-159. The cotransport of sodium ions provides the driving force for 
the concentrative uptake of glutamate which is necessary for maintaining low 
extracellular CNS concentration of glutamate108. In addition, EAAT4 and EAAT5 
possess ion channel like properties by adopting ligand-gated chloride conductance 
of substrate transport.  
 
3.4.2 The Excitatory Amino Acid Transporter 2 (EAAT2) 
 
The sodium coupled glutamate transporter EAAT2 is distributed abundantly on 
astrocytic plasma membranes associated with excitatory synaptic contacts160-162. It is 
abundantly expressed in all brain regions, including the hippocampus, lateral septum, 
cerebral cortex and striatum.  
 
EAAT2 is thermodynamically coupled to an inwardly directed sodium gradient. 
Glutamate influx is coupled to the cotransport of two to three sodium ions, one proton 
and the counter-transport of a potassium ion157-159. The current generated by EAAT2 
through Cl- conductance is relatively small106,108,163. It has two consensus N-linked 
glycosylation sites encoded in a large hydrophilic loop between 3rd and 4th 
transmembrane domains (TMs)108.  
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Among the five subtypes of human EAATs, EAAT2 is the most abundant 
transporter in the CNS. Together with EAAT1, EAAT2 has the greatest impact on 
clearance of glutamate released during neurotransmission107,140,141,160,162,164. As 
glutamate may exert neurotoxic effects, defective function or regulation of astroglial 
EAAT2 expression may foster neuroexcitotoxicity165-168. Lack of EAAT2 has indeed 
been shown to promote extracellular glutamate accumulation, excitotoxicity and 
ultimately cell death. EAAT2 dysfunction has been reported in amyotrophic lateral 
sclerosis (ALS)169. 
 
Despite the fundamental role of EAAT2 in CNS glutamate shuttling, only few 
studies have addressed the regulation of trafficking and function of this carrier. To 
date EAAT2 has been shown to be regulated by protein kinase C (PKC)153,170,171. 
PKC phosphorylates and internalizes EAAT2149,151-153.  
 
In the present study, coexpression experiments in Xenopus laevis oocytes 
have been used to examine the influence of SGK1, its isoforms SGK2 and SGK3 and 
the related protein kinase PKB on the glial glutamate transporter EAAT2. 
 
3.4.2.1 The Excitatory Amino Acid Transporter 4 (EAAT4) 
 
EAAT4 belongs to the family of sodium coupled glutamate transporters, which 
is predominantly expressed on a GABAergic cell type, the cerebellar Purkinje cells 
which are particularly sensitive to neuronal death and appears to be concentrated in 
dendritic areas that receive major glutamatergic inputs106,172.  
 
To escape neuroexcitotoxicity, Purkinje cells clear extracellular glutamate by 
Na+ coupled uptake, a function served by the glutamate transporter EAAT4143. 
During ischemia, lack of EAAT4 correlates with loss of Purkinje cells supporting a 
role of EAAT4 in the protection of those cells173. Efficient neuronal protection would 
require the adjustment of EAAT4 activity to the demand.  
 
As like EAAT2, the transport of glutamate by EAAT4 is thermodynamically 
driven by an inwardly directed sodium gradient. Glutamate influx is coupled to the 
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cotransport of two to three sodium ions, one proton and the counter-transport of a 
potassium ion157-159. EAAT4 also shows ligand gated chloride conductance as like 
EAAT5123,134,174. The EAAT4 sequence bears three N-linked glycosylation sites and 
two putative SGK1 consensus sites (Thr40 and Thr504) at the amino and carboxy 
terminus that are conserved among several species.  
 
The presence of the SGK1 consensus sites on the EAAT4 protein sequence 
suggests that the transporter might be directly phosphorylated by SGK1. In a 
previous study, EAAT4 activity and plasma membrane expression was shown to be 
upregulated by SGK1. The mechanism of SGK1 action remained however elusive. 
From ENaC regulation studies, SGK1 was found to stimulate the activity and the 
expression of ENaC by hindering the downregulating effect of the protein ubiquitin 
ligase Nedd4-2, but this mechanism of SGK1 action has not yet been demonstrated 
in the SGK1 mediated regulation of EAAT4. 
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4 Aim of the Study 
 
The Serum and Glucocorticoid inducible protein Kinase 1 (SGK1) is well 
known to upregulate several ion channels and transporters such as the epithelial 
Na+ channel, ENaC, the renal chloride channel ClC-Ka/barttin, the K+ channel 
ROMK, the excitatory amino acid transporter EAAT4, and the sodium dependent 
glucose transporter SGLT1. The kinase exert its effects directly through 
phosphorylation of its targets or indirectly through inhibition of the ubiquitin ligase 
which otherwise tag its targets for internalization and degradation. 
 
The major aim of this current work was to study the putative regulation of two 
sodium dependent glutamate transporters, EAAT2 and EAAT4, by SGK1 and 
Nedd4-2 in the Xenopus laevis oocyte expression system. Considering the key role 
of EAAT2 in regulating glutamate concentrations in the CNS, the elucidation of a 
regulatory mechanism of EAAT2 function and expression might have important 
implications in the regulation of neuroexcitability in health and disease.  
 
This study aimed not only at investigating the significance of SGK1 in EAAT2 
modulation but also of its isoforms SGK2 and SGK3 as well as PKB. Given that the 
closely related glutamate transporters EAAT1 is modulated by SGK1 in part through 
interference with the downregulating effect of the ubiquitin ligase Nedd4-2, the 
present work addressed whether the kinases modulate EAAT2 by impeding Nedd4-
2 effects. The possibility that SGK1 and Nedd4-2 affect each others expression was 
also considered.  
 
Recent studies demonstrated the ability of SGK1 to stimulate the activity and 
plasma membrane abundance of the excitatory amino acid transporter 4 (EAAT4). 
However the mechanism of SGK1 action remained elusive.  
 
The present work was driven to identify the molecular mechanism of EAAT4 
modulation by the kinase. The EAAT4 protein sequence bears two putative SGK1 
phosphorylation sites which suggest SGK1 direct phosphorylation as the 
mechanism of EAAT4 modulation by the kinase. Here we investigated whether 
none, both or only a unique site is required for the SGK1 stimulatory effect. Nedd4-
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2 has also been reported to modulate EAAT4 activity. Thus, SGK1 might enhance 
EAAT4 by inhibiting intrinsic Xenopus Nedd4-2. This mechanism of SGK1 action 
was also analysed.  
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5 Materials and Methods 
5.1 Site Directed Mutagenesis 
 
In order to quantify surface abundance of EAAT2 and EAAT4 on the oocytes 
membrane, an hemagglutinin tag (HA-tag) was introduced in an extracellular loop 
of transporters by two-stage PCR site-directed mutagenesis. The expression of HA-
tagged transporters could be detected by a chemiluminescence assay by using an 
anti-HA antibody.  
 
At the first stage of the two-stage PCR site-directed mutagenesis, two 
separate PCR reactions were performed, one with the forward primer and another 
with the reverse primer (Table 1) containing the HA sequence flanked by EAAT2 
and EAAT4 specific sequences. In the second stage, the PCR products were mixed 
and further amplified as a single reaction. The first PCR consisted on 4 cycles of 
30s at 94°C; 30s at 95°C; 1min at 55°C; 2 min at 68°C and the second PCR 
consisted on 18 cycles of 30s at 94°C; 30s at 95°C 1min at 55°C; 2 min at 68°C. 
Table 2 indicates the composition of the PCR mixture as suggested by Stratagene 
(Heidelberg, Germany). Figure 8 shows a schematic outline of two-stage site-
directed mutagenesis method. 
 
 
Protein 
 
Forward Primer Reverse Primer 
 
EAAT2-HA 
5´GTCCAGCCTGGATTAC
GACGTACCAGATTACGC 
TGCCTTCCT GGACC 3´ 
5´GGTCCAGGAAGGCA
GCGTAATCTGGTACGT
CGTAATCCAGGCTGGA
C 3´. 
 
EAAT4-HA 
5´ GGGTCAGAGTTGGGG 
TACGACGTACCAGATTAC 
GCTGCCTCCATTTCTCC 
3´ 
5´ GGAGAAATGGAGG 
CAGCGTAATCTGGTAC
GTCGTACCCCAACTCT 
GACCC 3´. 
 
Table 1 Forward and reverse primers used to generate EAAT2-HA and EAAT4-HA. 
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PCR reaction mixture Quantity 
10X Pfu buffer 5 µl 
10 mM primer 1 µl 
Plasmid template 0.1 – 0.2 µg 
10 mM dNTP mix 1 µl 
H2O Final volume of 50 µl 
Pfu turbo polymerase 1 µl 
 
Table 2 PCR reaction mixture for two-stage PCR site-directed mutagenesis.  
 
 
 
Figure 8 Main steps of two-stage PCR site-directed mutagenesis.  
 
The final PCR product contains a mixture of wildtype and mutated plasmid 
DNA. In order to get rid of the wildtype DNA, the PCR product was digested with 1 µl 
of Dpn I enzyme (10U/ µl) which only digests methylated parent (template) DNA. The 
Dpn I digested PCR product was then transformed into E.coli XL1-Blue 
Supercompetent cells by a heat shock method and plated onto LB plates. Grown 
Two-stage PCR site-directed mutagenesis
Forward and reverse primer containing HA
sequence are used to introduce HA tag into
EAAT2/4 gene in two separate PCR reactions
Template DNAs with inserted HA gene from
previous step are mixed together and further
amplified by PCR
Amplified template DNA contains the HA 
sequence in EAAT2/4 gene
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bacteria were picked and inoculated into LB media for further DNA isolation and RNA 
synthesis. Mutants were sequenced to verify the presence of the desired mutation. 
 
The site-directed mutagenesis technique was also performed to eliminate 
putative SGK1 phosphorylation sites on EAAT4. The phosphorylation sites at Thr40 
and Thr504 position on EAAT4 were eliminated separately to generate T40AEAAT4, 
T504AEAAT4 single mutants according to the manufacturer’s (QuikChange site-
directed mutagenesis kit, Stratagene, Heidelberg, Germany) instructions. By using 
T40AEAAT4 as a template, phosphorylation site at Thr504 position on EAAT4 was 
eliminated to generate the double mutant T40AT504AEAAT4 which lacks both SGK1 
phosphorylation sites. These mutants were used to study the stimulation of EAAT4 
activity and plasma membrane abundance by SGK1 in the absence of one or both 
phosphorylation sites. The primers used to generate these mutants are listed in 
Table 3 below. All other mutants used in this work were prepared by other 
collaborators. Table 4 indicates the composition of the PCR mixture as suggested 
by Stratagene (Heidelberg, Germany).  
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Protein Forward Primer Reverse Primer 
 
T40AEAAT4 
 
5´ CGCTTGCGCCTGCAG 
GCCATGACCCGAGAGC 
3´ 
 
5´ CCCCAAGTACA 
TTGGCCATCGTAC 
GAAGTCG 3´ 
 
T504AEAAT4 
 
5´ GCTCTCGGGTCATGG 
CCTGCAGGCGCAAGCG 
3´. 
 
5´ CCCCAAGTACAT 
TGGCCATCGTACG 
AAGTCG 3´ 
 
S356DSGK2 
 
5´ GCATTCCTGGGATTTG 
ATTATGCGCCAG AGG 3´. 
5´ CCTCTGGCGCAT 
AATCAAATCCCAGG
AATGC 3´. 
S419DSGK3 5´ GATGCATTCGTTGGTT 
TCGATTATGCACCTCCTT
CAG 3´. 
5´ CTGAAGGAGGTG 
CATAATCGAAACCA
ACGAATGCATC 3´. 
 
Table 3 Forward and reverse primers used to generate T40AEAAT4, T504AEAAT4, 
S356DSGK2 and S419DSGK3. 
 
PCR reaction mixture Quantity 
10 X reaction buffert 5 µl 
dsDNA template 5-50 ng 
Oligonucleotide primer 1 125 ng 
Oligonucleotide primer 2 125 ng 
dNTP mix 1 µl 
Pfu Turbo DNA polymerase 
(2.5 U/ µl) 
1 µl 
 
Table 4 PCR reaction mixture used to generate T40AEAAT4, T504AEAAT4 and 
T40AT504AEAAT4 mutants.  
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5.1.1 Transformation of E.coli XL1-Blue Supercompetent Cells 
 
E.coli XL1-Blue Supercompetent cells from Stratagene, (Heidelberg, 
Germany) were thawed on ice and 50 µl of the supercompetents cells were taken 
into a prechilled Falcon 2059 polypropylene tube. 1 µl of Dpn I-treated DNA sample 
was added to the aliquots of supercompetent cells. The tube was gently vortexed to 
mix the content and incubated on ice for 30 minutes. Transformation reaction was 
started by keeping the tube at 42ºC for 45 seconds which make bacteria to open 
their pores on the cell wall to provide entry of DNA and then suddenly placed on ice 
for 2 minutes which allows bacteria to close the cell wall pores.  
 
0.5 ml of preheated (42ºC) NZY broth was added to the heat-shock treated 
supercompetent cells and incubated at 37ºC for 1 hour with shaking at 220 rpm. 
Then 250 µl of DNA transformed bacterial cells were plated on agar plates. LB 
plates were incubated at 37ºC overnight.  
 
From LB plates several clones were picked and bacteria were grown in LB 
broth to get more quantity of bacterial cells to isolate transformed plasmids for 
further experiments. The mutant plasmids from E.coli cells were isolated and 
purified with Qiagen (Hilden, Germany) DNA plasmid midi purification kit according 
to the manufacturer’s instructions. The purified plasmids were sequenced to 
confirm the desired mutation.  
 
5.2 Preparation of cRNA 
 
To study the function and expression of transporters, cRNAs of transporters 
were injected into Xenopus laevis oocytes. The mutant DNAs including EAAT2-HA, 
T40AEAAT4, T504AEAAT4 and T40AT504AEAAT4, were used as a template to synthese 
cRNA. cRNAs of SGK and PKB kinases and Nedd4-2 were also synthesised by the 
same method. RNA synthesis protocol possesses two steps: linearization of the 
plasmid DNA containing the sequence of interest and generation of cRNA itself.  
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5.2.1 Plasmid DNA linearization 
 
The restriction endonuclease was used to make a cut at the 3’ end of the 
insert and to yield a 5’ blunt end. Specific restriction enzymes used to linearize 
each plasmid used in this study are shown in Table 5.  
 
Protein Plasmid Restriction 
Endonuclease 
S422DSGK1  pGHJ  Not I 
SGK2 and SGK3 pGHJ Not I 
PKB            pGHJ Sal I 
human Nedd4-2, and 
S382D.S468DNedd4-2 
pGHJ Hind III 
C962SNedd4-2 pGHJ Bgl II 
human EAAT2-HA pOTV Spe I 
rat EAAT4, EAAT4-HA, 
T40AEAAT4, T504AEAAT4 
and T40AT504AEAAT4 
pGHJ Xba I 
GLUT1 pSP64T Xba I 
 
Table 5 Plasmids containing desired gene encoding for specific proteins and 
restriction endonuclease enzymes used to linearzise each plasmid. 
 
The reaction mixture as mentioned in the table below was prepared and 
incubated at 37ºC for 2 hours. Then DNA was precipitated with 1 volume of 
isopropanol (50 µl) and 1/10 volume of 3 M sodium acetate, pH 5.2 (5 µl) and 
incubated at room temperature for 10 minutes. Reaction mixture was centrifuged at 
17000 rpm for 15 minutes at 4ºC. After removing the supernatant, the pellet was 
washed twice with 70 % ethanol (100 µl) at 17000 rpm for 10 minutes. Ethanol was 
removed from the last wash and the pellet was dried using the Eppendorf 
Concentrator (Eppendorf, Hamburg, Germany) at 35-45º C for 5 minutes. 
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Reaction mixture Quantity 
10X Buffer 5 µl 
Plasmid DNA (10 µg) 20 µl 
Restriction enzymed (20U) 2 µl 
Water 23 µl 
 
Table 6 Reaction mixture used to linearize plasmidic DNA. 
 
5.2.2 cRNA synthesis 
 
The linearized DNA produced from the above mentioned method was used 
as a template to generate cRNA. The reaction mixture given in table 7 was taken in 
a sterile eppendorf tube. 
 
Reaction mixture Quantity 
Linearised DNA (1 µg) 10 µl 
10 X Buffer 2.5 µl 
rNTPs 1 µl 
Cap analogue 2.5 µl 
RNase inhibitor 1 µl 
Water 8 µl 
 
Table 7 Reaction mixture used to synthesis RNA from the linearized DNA.  
 
The reaction mixture was gently spanned and appropriate RNA polymerase 
(Table 8) was added and pulse spanned again. The reaction mixture was incubated 
at 37ºC when using T3 or T7 polymerases or at 40ºC when using SP6 polymerase 
for 1 hour. Then 1 µl of Dnase was added to remove the possible DNA 
contamination in the reaction mixture. Finally reaction mixture was incubated at 
37ºC for 15 min by shaking. 
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Protein RNA Polymerase cRNA (ng/oocyte) 
S422DSGK1, S356DSGK2 
and S419DSGK3 
T7 7.5 
PKB T7 7.5 
human Nedd4-2, 
C962SNedd4-2 and 
S382D.S468DNedd4-2 
Sp6 12.5 
human EAAT2-HA T7 10 
rat EAAT4, EAAT4-HA, 
T40AEAAT4, T504AEAAT4 
and T40AT504AEAAT4 
T7 10 
Glut1 Sp6 1 
 
Table 7 RNA polymerases used to prepare cRNA and amount of cRNA injected into 
oocytes.  
 
To purify the generated RNA, 100 µl DEPC water and 125 µl of phenol-
chloroform mixture was added and centrifuged at maximum speed for 2 minutes. 
The upper inorganic phase was carefully taken into a new eppendorf tube and 12.5 
µl of 3 M sodium acetate (pH 5.2) and 375 µl of 100% ethanol was added and 
mixed by pulse vortex and further incubated at -70 ºC overnight.  
 
After incubation, the mixture was centrifuged at 17000 rpm for 15 minutes at 
4 ºC. The supernatant was removed and the pellet was washed twice with 200 µl of 
70% ethanol. Finally the pellet was dried at room temperature and reconstituted in 
25 µl of DEPC water and vortexed. Then concentration of RNA was measured by 
taking 1 µl of RNA in 69 µl water using an Eppendorf Biophotometer (Hamburg, 
Germany). The quality of the RNA generated was checked by gel electrophoresis.  
 
5.3 Xenopus laevis oocyte preparation 
 
Xenopus laevis oocytes were used as an expression system to study 
function and plasma membrane abundance of transporters. Prior to isolation of 
oocytes, female Xenopus laevis frogs were anaesthetized by submersion in a 0.1% 
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3-aminobenzoic acid ethyl ester solution (Sigma, St. Louis, Mo, USA) for 15-20min 
and placed on ice for surgery. Through a small abdominal incision (1-2 cm in 
length) small pieces of ovary were removed carefully without injuring any blood 
capillaries and the wound was subsequently closed with a reabsorbable suture. 
Frogs were kept wet but not under water until reflexes were fully recovered to 
prevent drowning.  
 
The ovarian sacs were manually tore apart and oocytes were separated with 
fine tweezers in OR2 solution (82.5 mM NaCl, 2 mM KCl, 1mM MgCl2 and 5 mM 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.5). Enzymatic 
defolliculation was achieved by treatment of ovarian lobes with OR2 solution with 1 
mg/ml collagenase (Biochrom, Berlin, Germany) for about 60-120 min at room 
temperature. The flask was slightly shaken to ensure even digestion.  
 
To stop defolliculation, oocytes were repeatedly washed with ND96 (96 mM 
NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, and 5 mM HEPES, pH 7.65) to 
remove all detritus and collagenase. Large oocytes (stage V-VI) showing evenly 
coloured poles and a sharp border between both poles were selected and stored 
overnight in a ND96 storage solution (complemented after sterilisation with 5 mM 
pyruvate, 50 µg/ml gentamycin and 0.5 mM theophylline) at 15 °C. Gentamycin 
helps preventing infections and theophylline inhibits the further maturation of the 
oocytes. Figure 9 depicts oocyte preparation and cRNA injection.  
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Oocytes preparation and injection
Frog was operated and oocytes were separated
from ovarian sacs, then treated with collagenase
After collagenase treatment oocytes were washed,
sorted (stage V and VI) and incubated in ND 96 at 15ºC
Sorted oocytes were injected with cRNA and again
Incubated in ND 96 at 15º C
 
 
Figure 9 An overall view of oocytes preparation, cRNA injection and protein 
expression in oocytes.  
 
5.4 Protein expression in Xenopus laevis oocytes 
 
Oocytes were injected with kinases S422DSGK1, S356DSGK2, S419DSGK3 and 
T308D, S473DPKB cRNA and/or wild type or mutated Nedd4-2 cRNA or H2O on the first 
day after preparation of the oocytes and subsequently with EAAT2-HA, EAAT4 or 
its mutant cRNAs next day. For RNAi, experiments 1.5 ng of double-stranded 
siRNA 19-mer oligo (Invitrogen Corporation, Carlsbad, California, USA) 
corresponding to bases 2707-2725 of xNedd4-2 was injected into oocytes on the 
first day and then next day oocytes were injected with S422DSGK1 and EAAT4-HA in 
two hours interval.  
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On the fifth day of kinase injection tracer uptake measurement was carried 
out to study the activity of the transporters. On the same day chemiluminescence 
assay was performed to study the plasma membrane abundance of the 
transporters. Oocytes were lysed and proteins isolated to perform western blotting 
to address proper protein expression and assessment of RNAi gene silencing at the 
protein level. 
 
5.5 Nedd4-2 RNA Silencing by siRNA 
 
The indirect mechanism of EAAT4 stimulation by SGK1 through inhibiting the 
downregulating effect of Nedd4-2 could be analysed by silencing Nedd4-2 of 
Xenopus oocytes. The small interfering RNA (siRNA) technique was employed to 
silence the intrinsic Nedd4-2. Using Ambion® siRNA Target Finder, siRNA for 
Nedd4-2 was designed online. Chosen siRNA corresponds to bases 2707-2725 of 
xNedd4-2 within is the catalytically active region. Chemically synthesized Nedd4-2 
siRNA was bought from Invitrogen Corporation (Carlsbad, California, USA). Figure 
10 depicts siRNA mode of action. The silencing activity of siRNA starts with the 
introduction of a long piece of double stranded RNA (dsRNA) into the eukaryotic 
cell. In the natural pathway, the dsRNA is sliced into smaller pieces by an enzyme 
named ‘dicer’. The small pieces of RNA are called small interference RNA (siRNA) 
which complex with a number of proteins and form RNA-induced silencing complex 
(RISC). RISC unwinds siRNA into single strand and thereby RISC-siRNA complex 
targets mRNA. The targeted mRNA hybridizes with and is degraded by the siRNA.  
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Enzyme ‘dicer‘ cleaves the
long dsRNA into siRNAs
RNA-induced silencing
Complex (RISC)
RISC cleaves target
mRNA
Short interfering RNA (siRNA)
 
 
Figure 10 Schematic representation of siRNA mode of action. 
 
1.5 ng of double-stranded siRNA 19-mer oligo was injected into oocytes on 
the first day after oocytes´ preparation and EAAT4 and/or SGK1 was injected on 
the following day. On the fifth day of the injection tracer flux measurement was 
done to observe the activity of the transporter coexpressed with siRNA and/or with 
SGK1. For the assessment of RNAi gene silencing at the protein level, oocytes 
were lysed on the same day that functional experiments were performed and 
western blotting was carried out as described below. 
 
5.6 Tracer Flux Measurements 
 
Function of the transporters was demonstrated by means of tracer flux 
measurements. The transport assay was performed on the fifth day after cRNA 
  Materials and Methods 
42 
injection. 5-10 single oocytes were incubated in 500 µl of ND96-Na (96 mM NaCl, 2 
mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.65) containing 1 µCi 
[3H] L-glutamate and 10 µM of unlabelled L-glutamate and another set with the 
same number of oocytes were incubated in ND96-Ch (96 mM ChCl, 2 mM KCl, 1.8 
mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, pH 7.65) where NaCl was substituted 
by choline chloride (ChCl).  
 
After incubation for 10 minutes with L-glutamate (linear range of uptake), 
uptake was terminated by washing the oocytes four times with 3 ml of ice-cold 
ND96-Na and ND96-Ch containing 1 mM unlabelled L-glutamate. Oocytes were 
individually transferred into scintillation vials and dissolved by adding 200 µl of 10% 
SDS before the radioactivity was determined. Uptake values obtained with ND96-
Ch were always substracted from the values obtained with ND96-Na, because 
EAAT2 and EAAT4 are sodium dependent glutamate transporters which uptake 
glutamate with influx of two to three sodium ions and one proton with efflux of one 
potassium ion.   
 
For determination of GLUT1 activity, tritium-labeled 2-deoxy-D-glucose ([3H] 
2-DOG) was used as the glucose analogue. The GLUT1 transport assay was 
performed 4 days after cRNA injection and contained 5-10 single oocytes in 0.25 ml 
of ND96 (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2 and 5 mM HEPES, 
pH 7.4) containing 1 µCi of [3H] 2-DOG and 50 µM of unlabelled 2-DOG. After 
incubation for 30 min at room temperature with 2-DOG (linear range of uptake), 
uptake was terminated by washing the oocytes four times with 3 ml of ice-cold 
ND96. Oocytes were individually transferred into scintillation vials and dissolved by 
adding 200 µl of 10% SDS before the radioactivity was determined. 
 
5.7 Detection of Cell Surface Expression by Chemiluminescence  
 
To quantify abundance of the transporters expressed on the plasma 
membrane of oocytes, chemiluminescence assay was employed. On the fifth day of 
kinase injection oocytes were incubated in 400 µl of ND96 with 1% BSA solution for 
20 min at room temperature as a blocking step. Oocytes were then incubated with 1 
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µg/ml primary rat monoclonal anti-HA antibody (clone 3F10, Boehringer, Germany), 
which can detect the haemagglutin tag inserted into the extracellular loops of EAAT2 
and EAAT4 in 200µl of ND96 with 1%BSA solution.  
 
After an hour of incubation at room temperature, oocytes were washed with 
400 µl of ND96 with 1% BSA for 5 times in 30 minutes. 2 µg/ml secondary, 
peroxidase-conjugated affinity-purified F(ab’)2 goat anti-rat IgG antibody (Jackson 
ImmunoResearch, West Grove, USA) was added to oocytes in 200 µl of ND96 with 
1% BSA and incubated for 1 hour. Oocytes were again washed with 400 µl of ND96 
with 1% BSA for 10 times in one hour. Finally oocytes were washed with 400 µl of 
ND96 alone for 3 times in 15 min.  
 
Individual oocytes were placed in 96 well plates with 100 µl of ND96 and 20 µl of 
SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce, Rockford, USA), 
was added to each well. Chemiluminescence was quantified in a luminometer (Wallac 
Victor 2 plate reader, Perkin Elmer, Juegesheim, Germany) by integrating the signal 
over a period of 1 second. Results are given in relative light units (RLU).  
 
RLU obtained with H2O-injected oocytes (control oocytes) were substracted 
from the values obtained with oocytes injected with EAAT2-HA and EAAT4-HA alone 
or together with the respective SGK isoforms and/or Nedd4-2. In the relevant range of 
protein expression, the chemiluminescence amplitude correlates linearly with the 
protein abundance at the cell membrane175. Figure 11 shows an overview of the 
performed cell surface assay.  
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Cell surface expression
Oocytes treated with primary and secondary
antibodies
Primary
antibody
Secondary
antibody
Substrate Product + Light
Site directed
mutagenesis
Insertion of haemagglutinin (HA)
tag by site directed mutagenesis
HA tag
Oocytes treated with primary and secondary
antibodies
Luminometer
 
Figure 11 Overall view of a chemiluminescence-based cell surface experiment. 
 
5.8 Western Blotting 
 
The expression of SGK1, Nedd4-2 and GAPDH was analyzed by western 
blotting. Briefly, oocytes were homogenized in lysis buffer containing 50 mM Tris (pH 
7.5), 0.5 mM EDTA (pH 8.0), 0.5 mM EGTA, 100 mM NaCl, 1 % Triton X-100, 100 µM 
sodium orthovanadate and protease inhibitor cocktail (Roche, Mannheim, Germany) 
at the recommended concentration.  
 
Proteins were separated on an 8 % polyacrylamide gel and transferred to 
nitrocellulose membranes. After blocking with 5 % non-fat dry milk in PBS / 0.15 % 
Tween 20 for 1h at room temperature, blots were incubated overnight at 4°C with a 
rabbit Nedd4-2 antibody (diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry 
milk), a rabbit anti-SGK1 antibody (Upstate, Waltham, MA, USA, diluted 1:1000 in 
PBS / 0.15 % Tween 20 / 5 % non-fat dry milk) or a rabbit anti-GAPDH HRP 
conjugated antibody (Santa Cruz Biotechnology, Heidelberg, Germany, diluted 
1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry milk). GAPDH was used to 
demonstrate equal amount of protein loading. Secondary peroxidase-conjugated 
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sheep anti-rabbit IgG (diluted 1:1000 in PBS / 0.15 % Tween 20 / 5 % non-fat dry 
milk) were used for chemiluminescent detection with enhanced chemiluminescent 
ECL kit (Amersham, Freiburg, Germany). Band intensities were quantified using 
Quantity One® Analysis software (Biorad, Munich, Germany). 
 
5.9 Statistical Analysis 
 
Data are provided as means ± SEM, n represents the number of oocytes 
investigated. All experiments were repeated with at least 3 batches of oocytes; in all 
repetitions qualitatively similar data were obtained. All data were tested for 
significance using ANOVA, and only results with P < 0.05 were considered as 
statistically significant. 
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6 Results 
 
6.1 Modulation of EAAT2 by SGK1-3 and PKB 
6.1.1 SGK1 stimulates EAAT2 activity and plasma membrane abundance 
 
To evaluate the role of SGK1 in EAAT2 regulation, the transporter was 
expressed in Xenopus laevis oocytes in the absence and presence of the kinase and 
[3H] L-glutamate uptake was determined as a measure of EAAT2 activity. S422DSGK1-
mediated glutamate uptake increased upon coexpression of SGK1 (from 1.94 ± 0.38 
pmol/10 min/oocyte in EAAT2-HA expressing oocytes to 3.52 ± 0.32 pmol/10 
min/oocyte in oocytes coexpressing EAAT2-HA with S422DSGK1, n= 22) (Figure 12). 
Increased EAAT2 activity could be caused by enhanced expression of the transporter 
in the plasma membrane. To determine EAAT2 plasma membrane abundance we 
performed chemiluminescence assays by using an anti-HA antibody that recognizes 
an HA tag placed in an extracellular loop within the EAAT2 sequence (EAAT2-HA). 
Data obtained demonstrate that S422DSGK1 stimulates EAAT2 plasma membrane 
expression up to two fold (n= 35-37, Figure 13).  
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Figure 12 S422DSGK1 stimulates the activity of EAAT2-HA when coexpressed in 
Xenopus laevis oocytes. Arithmetic means ± SEM. * indicates statistically significant 
difference to uptake in Xenopus oocytes expressing EAAT2-HA alone. n= 21-23.  
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Figure 13 SGK1 stimulates the plasma membrane abundance of EAAT2-HA when 
coexpressed in Xenopus laevis. Arithmetic means ± SEM. * indicates statistically 
significant difference to the EAAT2 abundance in Xenopus oocytes expressing 
EAAT2-HA alone. n= 35 - 37. 
 
6.1.2 SGK1 isoforms SGK2-3 and PKB similarly stimulate Nedd4-2 
plasma membrane abundance 
 
To explore whether the SGK1 isoforms (SGK2-3) and PKB are also able to 
increase glutamate transport mediated by EAAT2, the different constitutively active 
SGK kinase isoforms were coexpressed with the transporter and labelled glutamate 
uptake was measured. Figure 14 shows that S356DSGK2 and S419DSGK3 upregulate 
EAAT2 as well (from 1.94 ± 0.38 pmol/10 min/oocyte in EAAT2-HA expressing 
oocytes to 4.72 ± 0.54 pmol/10 min/oocyte and 5.99 ± 0.87 pmol/10 min/oocyte in 
oocytes coexpressing EAAT2-HA with S356DSGK2 and S419DSGK3 respectively, n= 
23). We also quantified cell surface expression of the carrier in the presence of 
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S356DSGK2 and S419DSGK3. As demonstrated in Figure 15, carrier abundance in the 
oocyte membrane was similarly upregulated up to 2.3 fold by S356DSGK2, S419DSGK3 
and T308D, S473DPKB (n= 35-37).  
 
H 2
0
EA
AT
2-
HA
EA
AT
2-
HA
+
S3
56
D S
GK
2
EA
AT
2-
HA
+
S4
19
D S
GK
3
[3 H
] L
-
G
lu
ta
m
a
te
 
u
pt
a
ke
(pm
o
l/1
0 
m
in
/o
oc
yt
e
)
0
2
4
6
8
*
*
 
 
Figure 14 S356DSGK2 and S419DSGK3 enhance the activity of EAAT2-HA when 
coexpressed in Xenopus laevis oocytes. Arithmetic means ± SEM. * indicates 
statistically significant difference to uptake in Xenopus oocytes expressing EAAT2-HA 
alone. n= 23.  
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Figure 15 S356DSGK2 and S419DSGK3 increase the plasma membrane abundance of 
EAAT2-HA when coexpressed in Xenopus laevis oocytes. * indicates statistically 
significant difference to the EAAT2 surface abundance in Xenopus oocytes 
expressing EAAT2-HA alone. n= 35-37. 
 
6.1.3 SGK1 enhances EAAT2 by inhibiting Nedd4-2 effects without 
altering Nedd4-2 expression 
 
EAAT2 does not bear any putative SGK1 phosphorylation site on its sequence, 
thus the transporter cannot be directly enhanced by the kinase. In order to test 
whether SGK1 is effective through inhibition of the ubiquitin ligase Nedd4-2, we 
analyzed the impact of several Nedd4-2 mutants on EAAT2 activity. We used a 
catalytically inactive C962SNedd4-2 and a Nedd4-2 mutant that mimics the 
phosphorylation state of Nedd4-2 when expressed with SGK1 (S382D, S468DNedd4-2). 
Both sites (S382D, S468D) have been shown to be phosphorylated by SGK1 and in 
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the context of ENaC regulation by Nedd4-2, phosphorylation at these sites prevents 
Nedd4-2 binding to ENaC60. We therefore evaluated whether C962SNedd4-2 and 
S382D, S468DNedd4-2 were capable to influence EAAT2 activity. As shown in Figure 
16, both mutants failed to modulate EAAT2 (from 2.09 ± 0. 89 pmol/10 min/oocyte in 
EAAT2-HA expressing oocytes to 1.89 ± 0.63 pmol/10 min/oocyte and 3.09 ± 1.50 
pmol/10 min/oocyte in oocytes coexpressing EAAT2-HA with C962SNedd4-2 and S382D, 
S468DNedd4-2 respectively, n= 22). Additional expression of S422DSGK1 augmented 
the transporter activity (from 2.09 ± 0. 89 pmol/10 min/oocyte in EAAT2-HA 
expressing oocytes to 3.01 ± 0.69 pmol/10 min/oocyte in oocytes coexpressing 
EAAT2-HA with S382D, S468DNedd4-2 and S422DSGK1, n= 22). Thus, the kinase 
stimulates EAAT2 at least by indirectly inhibiting the ubiquitin ligase Nedd4-2. 
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Figure 16 SGK1 promotes EAAT2-HA activity indirectly through inhibiting the ubiquitin 
ligase Nedd4-2. Neither the Nedd4-2 mutant mimicking its phosphorylation state by 
SGKs (S382D, S468DNedd4-2) nor the mutant C962SNedd4-2 bearing a destructed catalytic 
domain modify [3H] – L-glutamate uptake. * indicates statistically significant difference 
to glutamate uptake in oocytes expressing EAAT2-HA alone n= 22.  
 
Coexpression of SGK1 could impact EAAT2 activity and expression. To rule 
out the possibility that SGK1 inhibits Nedd4-2 by downregulating Nedd4-2 expression, 
western blots were performed. According to immunoblotting Nedd4-2 protein 
abundance was unaffected upon coexpression of S422DSGK1 (Figure 17). The SGK1 
isoforms, SGK2-3, were also unable to modulate Nedd4-2 expression. Thus, SGKs 
impact Nedd4-2 activity while leaving Nedd4-2 levels unaffected.  
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Figure 17 SGK1-3 expression in oocytes does not affect the expression levels of 
Nedd4-2. The histogram depicts the quantification of the Nedd4-2 band intensities 
from three different western blots. All data were normalized to cells expressing EAAT2 
+ Nedd4-2. Arithmetic means ± SEM. 
 
SGK1 contains a PY motif, a target structure that is recognized by Nedd4-2. 
Thus, Nedd4-2 could bind to and ubiquitinate the protein kinase, preparing it for 
degradation by the proteosome. To clarify whether Nedd4-2 downregulates SGK1 
expression, the ubiquitin ligase was coinjected with SGK1 at different concentrations 
and SGK1 expression was analyzed by western blotting (Figure 18). SGK1 band 
intensities quantification demonstrated that Nedd4-2 does not significantly alter SGK1 
expression.  
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Figure 18 SGK1 expression remains unaltered upon Nedd4-2 overexpression. 
Immunoblots with a specific SGK1 antibody showed that expression of the kinase is 
not modulated by the ubiquitin ligase Nedd4-2. The histogram depicts the quantification 
of the SGK1 band intensities from three different western blots. All data were normalized 
to cells expressing EAAT2 + SGK1. Arithmetic means ± SEM.  
6.2 Modulation of EAAT4 by SGK1 
6.2.1 SGK1 enhances EAAT4 mediated glutamate transport 
 
In order to investigate the mechanism of EAAT4 activity modulation by 
SGK1, EAAT4 was expressed in Xenopus laevis oocytes and glutamate transport 
measured in the presence and absence of constitutively active S422DSGK1. On the 
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fifth day of kinase cRNA injection, labelled L-glutamate uptake was studied as a 
measure of EAAT4 activity.  
 
Tracer-flux studies revealed an increase in EAAT4 transport rate (223.132 ± 
41.17 % of control, n = 18, Figure 19) upon coexpression of S422DSGK1. Glutamate 
uptake into water injected oocytes was less than 42.41 ± 18.55 % of control (n= 
21).  
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Figure 19 SGK1 expression in EAAT4-injected oocytes enhances the activity of 
EAAT4. Arithmetic means ± SEM. * indicates statistically significant difference to 
uptake in Xenopus oocytes expressing EAAT4 alone. Uptake values were normalized 
in each batch of oocytes to the mean value obtained in oocytes expressing EAAT4 
alone. n= 21.  
6.2.2 Disruption of the putative SGK1 phosphorylation sites (Thr40 and 
Thr504) on EAAT4 abrogates transporter stimulation 
 
EAAT4 contains two putative SGK1 phosphorylation sites on its sequence at 
Thr40 and Thr504 present at the cytosolic amino and carboxy termini, respectively. 
Both sites are highly conserved among species including human, mouse and rat 
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and thus suggests an important role of these residues in EAAT4 function and 
regulation. To determine whether SGK1 modulates EAAT4 uptake by 
phosphorylating EAAT4 directly, threonine at positions 40 and 504 in EAAT4 were 
mutated into alanine (T40AT504AEAAT4) by site-directed mutagenesis and its 
regulation evaluated upon coexpression of the kinase. Threonine replacement 
eliminates the putative phosphorylation site of SGK1 (Arg-Xaa-Arg-Xaa-Xaa-
Ser/Thr) on EAAT4, thus hypothetically SGK1 cannot act on that site. 
 
Xenopus oocytes were injected with wild-type EAAT4 or phosphorylation-
deficient T40AT504AEAAT4 alone or together with constitutively active S422DSGK1. On 
the fifth day of injection, labelled L-glutamate uptake was studied and western 
blotting of whole cell lysates performed. Disruption of the putative SGK1 
phosphorylation sites abrogated EAAT4 stimulation by S422DSGK1 (from 77.31 ± 
13.23 % of control, n = 23, in T40AT504AEAAT4 expressing oocytes to 63.23 ± 10.80 
% of control, n = 22, in oocytes expressing T40AT504AEAAT4 along with S422DSGK1), 
suggesting that the kinase is effective through direct EAAT4 phosphorylation 
(Figure 20).  
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Figure 20 Mutant EAAT4 (T40AT504AEAAT4) with disrupted SGK1 phoshorylation sites 
failed to be stimulated by S422DSGK1. Proper S422DSGK1 expression was checked by 
western blotting. Arithmetic means ± SEM. * indicates statistically significant 
difference to uptake in Xenopus oocytes expressing wild-type EAAT4 alone. Uptake 
values were normalized to the mean value obtained in oocytes expressing wild-type 
EAAT4 alone. n= 22-23.  
 
6.2.3 Phosphorylation at Thr40 on EAAT4 is essential for transporter 
stimulation  
 
To delineate whether a unique or both phosphorylation sites are 
required for enhanced EAAT4 activity, single phosphorylation-deficient mutants 
were generated. The cRNAs of wild-type EAAT4, T40AEAAT4 or T504AEAAT4 alone 
or together with constitutively active S422DSGK1 were expressed in Xenopus 
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oocytes and on the fifth day of injection, labelled L-glutamate uptake was studied 
and western blotting of whole cell lysates performed. Coexpression of S422DSGK1 
with T504AEAAT4 promoted the transporter´s activity (from 100.51 ± 20.91 % of 
control, n = 9 to 192.71 ± 26.27 % of control, n = 9), whereas expression of the 
kinase failed to modulate T40AEAAT4 function despite normal SGK1 expression 
levels as assessed by western blotting of whole cell lysates (Figure 21). 
 
 
Figure 21 Upon coexpression of S422DSGK1, T504AEAAT4 activity is stimulated 
significantly while the activity of T40AEAAT4 remains unaltered. Western blotting 
confirmed proper SGK1 expression. Arithmetic means ± SEM. * indicates statistically 
significant difference to uptake in Xenopus oocytes expressing wild-type EAAT4 
alone. + indicates statistically significant difference to uptake in Xenopus oocytes 
expressing T504AEAAT4 alone. Uptake values were normalized to the mean value 
obtained in oocytes expressing wild-type EAAT4 alone. n= 20.  
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6.2.4 Phosphorylation at Thr40 on EAAT4 is required for enhanced 
EAAT4 plasma membrane abundance  
 
Further experiments were performed to pursue whether ablation of SGK1 
phosphorylation sites in EAAT4 blunts the kinase effect on plasma membrane 
abundance. To investigate cell surface expression of wild type and EAAT4 mutants, 
fusion constructs containing a hemagglutinin (HA)-tag in an extracellular loop were 
generated by two-stage site-directed mutagenesis and expressed in Xenopus 
oocytes.  
 
EAAT4 plasma membrane abundance examined by quantitative 
immunoassays revealed that the expression of the EAAT4 phosphorylation-
deficient (T40AT504AEAAT4) mutant was unaffected by SGK1 (from 101.44 ± 11.29 % 
of control, n = 53, in T40AT504AEAAT4 expressing oocytes to 104.72 ± 14.08 % of 
control, n = 42, in oocytes expressing T40AT504AEAAT4 along with S422DSGK1, Figure 
22). Phosphorylation at Thr40 appears to be responsible for the increased EAAT4 
abundance since T504AEAAT4 expression was augmented upon expression of the 
kinase (from 100.00 ± 9.15 % of control, n = 36 to 186.98 ± 28.58 % of control, n = 
36). 
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Figure 22 S422DSGK1 coexpressed with T504AEAAT4 enhances the plasma membrane 
abundance of the transporter noticeably. However, the kinase does not enhance the 
plasma membrane abundance when coexpressed with T40AT504AEAAT4. Arithmetic 
means ± SEM. * indicates statistically significant difference to oocytes injected with 
EAAT4 or T504AEAAT4 alone. Cell surface expression was normalized in each batch of 
oocytes to the mean RLU (Relative Light Units) value obtained in oocytes expressing 
EAAT4 alone. n= 36.  
 
6.2.5 Nedd4-2 coexpression inhibits the activity of EAAT4  
 
Prior to study the impact of silencing endogenous Nedd4-2 on the glutamate 
transporter activity, Nedd4-2 and EAAT4 were expressed in Xenopus oocytes and the 
effect of the ubiquitin ligase on EAAT4 was analyzed.  
 
EAAT4 cRNA alone or along with Nedd4-2 cRNA was injected in oocytes and 
its activity was measured on the fifth day after injection using tracer flux 
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measurements. Figure 23 shows the downregulation of EAAT4 activity upon Nedd4-2 
expression (58.65 ± 9.97% of control, n= 20).  
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Figure 23 Expression of the ubiquitin ligase Nedd4-2 downregulates EAAT4 activity 
significantly. Arithmetic means ± SEM. * indicates statistically significant difference to 
uptake in Xenopus oocytes expressing wild-type EAAT4 alone. Uptake values were 
normalized to the mean value obtained in oocytes expressing wild-type EAAT4 alone. 
n= 20.  
 
6.2.6 Silencing of intrinsic xNedd4-2 upregulates EAAT4 function 
 
SGK1 modulates several transporters indirectly through phosphorylation and 
thus inhibition of the ubiquitin ligase Nedd4-2, which otherwise tags its target 
protein for degradation38,60,176. 
 
Since Xenopus oocytes possess intrinsic Nedd4-2 (xNedd4-2), SGK1 could 
additionally be effective through xNedd4-2 inhibition. Silencing experiments using 
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the RNAi sequence-specific posttranscriptional silencing technique in Xenopus 
oocytes were performed to assess whether xNedd4-2 downregulation promotes 
EAAT4 activity.  
 
Oocytes were injected with EAAT4 alone or together with a double-stranded 
xNedd4-2 specific siRNA oligo. On the fifth day of cRNA injection, L-glutamate was 
measured. Functional studies showed enhanced EAAT4 activity in Nedd4-2 
silenced oocytes (256.67 ± 53.38 % of control, n = 14, Figure 24).  
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Figure 24 Significant enhancement of EAAT4 activity is noticed when intrinsic xNedd4-
2 is silenced in oocytes. S422DSGK1 expressed along with Nedd4-2 siRNA and EAAT4 
further enhances the transporters’ activity. Western blotting confirmed proper SGK1 
expression. Arithmetic means ± SEM. * indicates statistically significant difference to 
uptake in Xenopus oocytes expressing wild-type EAAT4 alone. Uptake values were 
normalized to the mean value obtained in oocytes expressing EAAT4. n= 14.  
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6.2.6.1 xNedd4-2 siRNA downregulates xNedd4-2 expression 
 
To demonstrate xNedd4-2 silencing, xNedd4-2 protein levels were analysed 
by western blotting. Oocytes injected with EAAT4 alone and with xNedd4-2 siRNA 
were lysed separately on the fifth day of injection and were analysed for Nedd4-2 
expression. Western blots confirmed the significant declination of intrinsic Nedd4-2 
expression.  
 
Densitometric analysis of Nedd4-2/GAPDH ratio of band intensities revealed 
a reduced (by two fold) Nedd4-2 expression in oocytes injected with xNedd4-2 
siRNA oligo (Figure 25). 
 
 
Figure 25 Western blot reveals the significant declination of intrinsic xNedd4-2 
abundance upon injection of Nedd4-2 siRNA. Nedd4-2/GAPDH band intensities from 
three independent experiments were normalized in each batch to the value of Nedd4-
2/GAPDH band intensity of oocytes expressing EAAT4 alone. 
 
6.2.6.2 xNedd4-2 siRNA does not alter GLUT1 expression 
 
To demonstrate the specificity of the effect observed, the activity of the 
facilitative glucose transporter GLUT1, that was previously reported to be 
unaffected by Nedd4-2, was studied upon injection of xNedd4-2 siRNA oligo. 
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GLUT1 function was not significantly altered by the coexpression of xNedd4-2 
siRNA (75.21 ± 9.65 % of control, n = 27, Figure 26). 
 
[3 H
] 2
 
D
O
G
 
u
pt
a
ke
(no
rm
a
liz
e
d)
0,0
0,2
0,4
0,6
0,8
1,0
1,2
H2
O
GL
UT
1
GL
UT
1 +
 
Ne
dd
4-2
 
siR
NA
GL
UT
1 +
 
Ne
dd
4-2
 
 
Figure 26 Injection of xNedd4-2 siRNA does not significantly alter GLUT1 expression, 
thus demonstrating Nedd4-2 siRNA specificity. Arithmetic means ± SEM. Uptake 
values were normalized to the mean value obtained in oocytes expressing GLUT1 
alone. n= 27.  
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7 Discussion 
 
The present data reveals two novel modulators of the sodium dependent 
glutamate transporters EAAT2 and EAAT4 namely the protein kinase SGK1 and the 
ubiquitin ligase Nedd4-2. SGK1 upregulates EAAT2 and EAAT4, while Nedd4-2 
downregulates both transporters. The EAAT2 transporter does not bear a SGK1 
consensus motif. Thus, the kinase modulates the transporter through an intermediate 
protein. We and others have shown that SGK binds to and phosphorylates Nedd4-2 
thus decreasing the affinity of the ubiquitin ligase to its target proteins60,177,178. 
Therefore, SGK1 might be effective through phosphorylation of Nedd4-2, an 
assumption supported by the observation that the Nedd4-2 mutant mimicking the 
SGK1-phosphorylated form does not impact EAAT2 function. However, the effect of 
Nedd4-2 is not completely abolished by SGK1, which may indicate that SGK1 cannot 
completely suppress Nedd4-2 function. On the other hand, SGK1 may not exclusively 
be effective through phosphorylation of Nedd4-2 and additional intermediatery 
proteins are yet to be identified.  
 
SGK1 enhances the carrier protein abundance. In a previous study utilizing 
brefeldin A, a drug interfering with the exocytotic pathway, we were able to 
demonstrate that SGK1 delays the clearance of transport proteins from the cell 
membrane31. However, in the case of EAAT2, it is not known whether delayed 
clearance of the transporter from the membrane causes its increased cell surface 
abundance. Further studies are required to clarify this issue. 
 
Nedd4-2 and SGK1 may participate in the signaling of neuroexcitability and 
neuroexcitotoxicity. According to the present results, Nedd4-2 would downregulate 
EAAT2 and thus delay the clearance of glutamate from the extracellular space. As a 
result the effects of glutamate may be enhanced. SGK1, on the other hand, is 
expected to accelerate the clearance of glutamate from the extracellular space and 
thus foster termination of an excitatory signal.  
 
Enhanced expression of EAAT2 has been shown to protect against excitotoxic 
neuronal death179,180 and deranged function of EAAT2 has been implicated in several 
neuronal diseases including amyotrophic lateral sclerosis169,181,182, epilepsy183-185 and 
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Alzheimer disease186,187. Moreover, lack of EAAT2 function was shown to potentiate 
retinal ganglion cell death188. In axotomy or after spinal cord injury, EAAT2 has been 
shown to be upregulated, an effect thought to play a protective role189,190 and 
overexpression of EAAT2 appears to protect against motor neuron degeneration and 
epilepsy. During ischemia, on the other hand, a reversed mode function of EAAT1 
and of EAAT2 has been postulated to enhance extracellular glutamate 
concentration191. Inappropriate regulation of the carriers by Nedd4-2 and/or SGK1 
could similarly participate in the pathophysiology of those diseases.  
 
The ability of SGK1 to stimulate EAAT2 activity is also observed with the 
isoforms SGK2 and SGK3 and with protein kinase B. Thus, these kinases have the 
potential to replace SGK1 in this functional capacity. This may be one reason for the 
apparently mild phenotype of the SGK1-knockout mouse192. Complete knockout of 
PDK1, i.e. the kinase upstream of all three SGKs and PKB, is not compatible with 
survival193. 
 
Taken together, the present study provides evidence that the serum and 
glucocorticoid inducible kinase isoforms SGK1, SGK2 and SGK3 and the related 
kinase PKB can regulate the glutamate transporter EAAT2. The kinases 
phosphorylate the ubiquitin ligase Nedd4-2 and thereby stimulate the activity and 
cell surface expression of EAAT2. The mechanism is likely to participate in the 
regulation of neuronal excitability. 
 
EAAT4 bears two putative SGK1 consensus sites (Thr40 and Thr504) that 
are highly conserved among several species suggesting that these sites might play 
a role in the transporter´s function. Our data provide evidence that the kinase 
modulates EAAT4 activity directly and that, from both putative SGK1 
phosphorylation sites, the residue Thr40 is essential for SGK1 induced stimulation 
of EAAT4 function and surface abundance. 
 
SGK1 is also capable to enhance the activity of other members of the 
excitatory amino acid transporter family (EAAT1, EAAT3 and EAAT5)38,39,41,194. 
Simillar to EAAT4, the glial transporter EAAT1 is upregulated by SGK1 in part via 
direct phosphorylation at a putative SGK1 consensus site (Thr482)38. EAAT1 
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function was enhanced by SGK1 in the presence of S382A, S468A Nedd4-2, while 
EAAT1 expressed alone with S382A, S468A Nedd4-2 showed a decrease in current.  
 
The transporters EAAT3 and EAAT5 do not contain any SGK1 
phosphorylation site in its sequence and might therefore be regulated indirectly or 
directly at a non-SGK1 consensus site. In the present study we further show that 
EAAT2 expression and activity is upregulated by SGK1 through phosphorylation 
and thus inhibition of the ubiquitin ligase Nedd4-2194. This mechanism of SGK1 
action is shared by EAAT1 and EAAT4, according to our present results on 
xNedd4-2 silencing in which EAAT4 activity was augmented in oocytes injected with 
xNedd4-2-specific siRNA oligos.  
 
The mechanisms by which SGK1 promotes EAAT3 and EAAT5 activity are 
still undefined. They might include the phosphorylation of a hitherto unknown 
intermediate protein since coexpression of a catalytically inactive SGK1 mutant 
failed to modulate the transporters41. 
 
Phosphorylation processes are known to modulate EAATs activity. Several 
growth factors that are neuroprotective enhance EAAT activities via activation of 
kinases: insulin-like growth factor-1 (IGF-1), epidermal growth factor receptor 
(EGFR) agonists and platelet-derived growth factor (PDGF) upregulate EAAT1, 
EAAT2 and EAAT3 respectively via phosphatidylinositol 3 kinase (PI3K) as 
demonstrated by PI3K inhibitors and constitutively active PI3K constructs195-197. 
Since SGK1 is activated by PI3K, the kinase might be the downstream effector in 
the PI3K signalling pathway activated by those growth factors. 
 
Besides, SGK1 itself is stimulated at gene transcriptional level by agonists 
such as mineralocorticoids4-6, follicle stimulating hormone (FSH) 7,8, transforming 
growth factor β (TGF-β) 9,10, and thrombin11. Stimulation of SGK1 may lead to the 
enhancement of other ion channels and transporters where SGK1 is localized. For 
instance, cerebellar SGK1 expression was enhanced in the cerebellar Purkinje cells 
of mice grown under dehydration condition, where EAAT4 predominantly express40. 
Accordingly SGK1 has the possibility to stimulate the EAAT4 activity in Purkinje 
cells under such stress conditions.  
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EAATs contain at least two putative phosphorylation sites for PKC and one 
for PKA198. Several reports have shown PKC and PKA modulation of glutamate 
transporters170,199-202. Activation of PKC enhances GLT1 (EAAT2) in Hela 
transfected cells and EAAC1 (EAAT3) in C6 Glioma cells170,199, whereas decreases 
GLAST activity in Bergmann glial cells147,148. 
 
Similar to SGK1, PKC modulates EAATs through different mechanisms: 
directly as a result of transporter phosphorylation at a putative PKC phosphorylation 
site (i.e. Ser113 on GLT1 sequence)170or indirectly through phosphorylation of 
intermediate proteins147. In contrast to SGK1, PKC modulates several EAATs by 
enhancing the transporter catalytical activity without altering its surface 
abundance170. 
 
In contrary to SGK1, Nedd4-2 was known to downregulate all members of 
the excitatory amino acid transporter family except for EAAT541,203. SGK1 
expressed along with Nedd4-2 and the EAATs (EAAT1-4) inhibited the 
downregulating property of Nedd4-2 and additionally enhanced EAAT1-4 activity38-
41,194,203
.  
 
In summary, the results presented here indicate that SGK1 modulates 
EAAT4 function and plasma membrane abundance via direct phosphorylation of the 
transporter. The residue Thr40 within the SGK1 consensus site present in EAAT4 is 
essential for the SGK1 stimulatory effects. SGK1 might additionally be effective 
through phosphorylation and thus inhibition of intrinsic ubiquitin ligase Nedd4-2 as 
suggested by our silencing experiments. Understanding the signalling mechanisms 
regulating EAAT4 may have significant implications for developing novel drugs to 
limit neuroexcitotoxicity. 
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